Food and Drug Administration, Weight and Zepbound

FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA approves weight loss drug Zepbound for sleep apnea
Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some pharmacies have practiced in mass-marketing copies of its highly popular GLP-1 medications.
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that weight-loss and diabetes drugs such as Lilly's (NYSE:LLY) tirzepatide are no longer in short supply.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
News Nation on MSN4d
Weight loss drug Zepbound approved to help sleep apnea patients
( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...
Hosted on MSN23d
Is Zepbound or Wegovy Better for Weight Loss? One Can Help You Shed 50 Lbs
The findings? Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these ...
CNN1mon
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
That translates to an average weight loss of about 50 pounds for those taking Zepbound, compared with an average weight loss of 33 pounds for those taking Wegovy. People taking Zepbound ...
UPI1mon
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...
NBC New York1mon
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
health.wusf.usf.edu13d
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea.
Arizona Couple Details 'Life-Changing’ Experience on Weight Loss Drugs — Including ‘Sulfur Burps’ (Exclusive)
Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...